R&D | May 28, 2026
Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Clearance marks major shift beyond chemotherapy
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
